EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Endogenous plasma riboflavin is not a viable BCRP biomarker in human

John P Savaryn, Ryota Kikuchi iD, Yuli Qian iD, Qin C Ji, Gary J Jenkins, Daniel A J Bow, Mohamed-Eslam F Mohamed iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von John P Savaryn und 6 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative, Translational and ADME Sciences, AbbVie Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Riboflavin, ATP Binding Cassette Transporter, Subfamily G, Member 2, Drug Interactions, Neoplasm Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent reports suggest that plasma riboflavin may serve as a biomarker for BCRP inhibition in humans. However, the clinical data supporting this claim have been limited, with only two studies showing modest increases in riboflavin levels after administration of a BCRP inhibitor. We have recently demonstrated that co‐administration of 375 mg once daily (q.d.) cedirogant, an in vitro BCRP inhibitor, significantly increased rosuvastatin (an OATP1B1/1B3 and BCRP substrate) exposures but did not change the levels of the OATP1B endogenous biomarker coproporphyrin‐I, demonstrating that cedirogant is a clinical BCRP inhibitor. Samples from this same cedirogant clinical drug–drug interaction study were utilized to test the hypothesis that endogenous plasma riboflavin is a biomarker of BCRP inhibition. Plasma riboflavin levels in the absence of cedirogant ranged from 1 to 10 ng/mL across the 11 participants analyzed with minimal (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RiboflavinATP Binding Cassette Transporter, Subfamily G, Member 2Drug InteractionsNeoplasm ProteinsBiomarkersHumansMaleAdultFemaleMiddle AgedRosuvastatin CalciumAdministration, Oral

Substanzen

RiboflavinATP Binding Cassette Transporter, Subfamily G, Member 2ABCG2 protein, humanNeoplasm ProteinsBiomarkersRosuvastatin Calcium

Autor:innen und Institutionen

  • Quantitative, Translational and ADME Sciences, AbbVie Inc., North Chicago, Illinois, USA.
  • Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.

ORCID-Profile: Ryota Kikuchi, Yuli Qian, Mohamed-Eslam F Mohamed

Zitieren

APA

Savaryn, J. P., Kikuchi, R., Qian, Y., Ji, Q. C., Jenkins, G. J., Bow, D. A. J., & Mohamed, M. F. (2024). Endogenous plasma riboflavin is not a viable BCRP biomarker in human. Clinical and Translational Science. https://doi.org/10.1111/cts.70109

Vancouver

Savaryn JP, Kikuchi R, Qian Y, Ji QC, Jenkins GJ, Bow DAJ, et al. Endogenous plasma riboflavin is not a viable BCRP biomarker in human. Clinical and Translational Science. 2024. doi:10.1111/cts.70109

BibTeX
@article{Savaryn2024,
  author = {Savaryn, John P and Kikuchi, Ryota and Qian, Yuli and Ji, Qin C and Jenkins, Gary J and Bow, Daniel A J and Mohamed, Mohamed-Eslam F},
  title = {Endogenous plasma riboflavin is not a viable BCRP biomarker in human},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.70109}
}
Kostenlos starten →